Overview: Anti-Gliadin IgG Antibody Rapid TestIntroduction: The Anti-Gliadin IgG Antibody Rapid Test is a diagnostic tool designed to detect Anti-Gliadin IgG antibodies in serum, whole blood, or saliva samples, facilitating the screening of celiac disease. These autoantibodies are indicative of gluten sensitivity, presenting with diarrhea, weight loss, and severe complications like malnutrition or lymphoma if untreated, particularly in genetically predisposed individuals. Per the 2023 American Gastroenterological Association guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in gastroenterology clinics. This rapid diagnostic falls under immunology and targets individuals with gastrointestinal symptoms or family history, addressing the challenge of early detection to guide gluten-free diet therapy. With morbidity rates elevated due to undiagnosed cases, the test supports public health efforts by enabling early identification, facilitating dietary management, and reducing long-term complications. Its multi-sample capability enhances its utility.Other Names: Anti-Gliadin IgG Rapid Test.FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Eurospital, this test advanced celiac disease detection, providing a rapid alternative to ELISA.Purpose: The test screens for Anti-Gliadin IgG to guide celiac disease diagnosis, assess disease risk, and inform treatment and prevention strategies.Test Parameters: Presence of Anti-Gliadin IgG Antibody, detected with reasonable specificity to indicate autoimmune activity, typically detectable in serum or blood during active gluten exposure.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report diarrhea, weight loss, or gluten-rich diet history.Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antibody integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on diarrhea, weight loss, bloating, or prior autoimmune conditions, as well as any family history of celiac disease or recent gluten intake.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated celiac disease including malnutrition, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent gluten-free diet can affect results. Correlation with biopsy or tTG testing is recommended to confirm findings.Clinical Significance: A positive result indicates possible celiac disease, necessitating further investigation like intestinal biopsy or gluten-free diet trial. A negative result may require follow-up testing if symptoms persist, especially if sampled after dietary changes.Specialist Consultation: Gastroenterologists should be consulted for case management, treatment planning, and coordination with autoimmune disease programs.Additional Supporting Tests: Intestinal biopsy, tTG, or Anti-Gliadin follow-up assays for confirmation.Test Limitations: The test may produce false negatives in early disease or false positives in other conditions, requiring a comprehensive diagnostic approach that includes clinical correlation.References: AGA Guidelines 2023, Gut 2024, Journal of Immunology 2025.